pharmacy

Gen-M 30Ml SpecificationRequires Prescription (YES/NO)YesGenericsArtemether , Lumefantrine Used ForMalariaHow it worksBoth components Artemether/ Lumefantrine have their own action site in the malarial parasite. The presence of the endoperoxide bridge in Artemether (generating single oxygen and free radicals, those are very cytotoxic to the plasmodia) appears to be essential for antimalarial activity.Gen-M 30Ml Usage And SafetyDosageArtemether , Lumefantrine Side EffectsVery Common: Palpitations, headache, dizziness, abdominal pain, anorexia, vomiting, nausea, arthralgia, mylagia, asthenia, fatigue, sleep disorders.Common: Amnesia, paraesthesia, diarrhea, pruritus, rash, cough, electrocardiogram QT prolongation, gait disturbances, insomia.Uncommon: Liver function test increased, clonus, hypoesthesia, ataxia, somnolence.Drug InteractionsCYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, cimetidine, HIV protease inhibitors, etc.) , CYP2D6 inhibitors (e.g. flecainide, metoprolol, imipramine, amitryptyline, clomipramine, etc.) , Mefloquine.IndicationUsed in the treatment of Malaria.When not to UseIt is contraindicated to those patients which have a history of hypersensitivity to Artemether / Lumefantrine.Gen-M 30Ml PrecautionsPrecautionDue to limited data on safety and efficacy, Artemether+Lumefantrine should not be given concurrently with any other anti-malarial agent unless there is no other treatment option.Gen-M 30Ml WarningsWarning 1Caution is advised when administering Artemether + Lumefantrine to patients with severe renal, hepatic or cardiac problems. In such cases, monitoring of the ECG is recommended and steps should be taken to correct any electrolyte disturbances.Warning 2Caution is recommended when combining Artemether + Lumefantrine with drugs exhibiting variable patterns of inhibition, induction or competition for CYP3A4 as the therapeutic effects of some drugs could be altered.Warning 3Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be greater.Gen-M 30Ml Additional InformationPregnancy categoryAlways consult your physician before using any medicine.Storage (YES/NO)Store this medicine at room temperature, away from direct light and heat.

Gen-M Iv/Im SpecificationRequires Prescription (YES/NO)YesGenericsArtesunateUsed ForMalariaHow it worksArtesunate is metabolized to the active DHA. the endoperoxide bridge of DHA reacts with heme, generating free radicals which inhibit protein and nucleic acid synthesis of the Plasmodium parasites during all erythrocytic stages.Gen-M Iv/Im Usage And SafetyDosageArtesunateSide Effects Drug induced fever , Cardiotoxicity , reduction in reticulocyte counts , dizziness, itching, vomiting, abdominal pain, flatulence, headache, body ache, diarrhoea, tinnitus and increased hair loss, macular rash, reduction in neutrophil counts and convulsions , skin rash and pruritus .Drug InteractionsAntioxidant drugs e.g. Vitamin E,C . Additive effect seen with chloroquine. Antagonistic effect seen with pyrimethamine and sulphonamides.IndicationTreatment of severe falciparum malaria in areas where there is evidence of quinine resistance.When not to UseThe drug is contraindicated in patients with prior hypersensitivity to artesunate or artemisinin derivatives.Gen-M Iv/Im PrecautionsPrecautionParenteral artesunate should be used for the treatment of severe falciparum malaria only where there is evidence that the antimalarial efficacy of quinine is declining.Gen-M Iv/Im WarningsWarning 1Monitor patients for 4 weeks after artesunate treatment with Artesunate for Injection for evidence of hemolytic anemia. Since a subset of patients with delayed hemolysis after artesunate therapy have evidence of immune-mediated hemolysis, consider performing a direct antiglobulin test to determine if therapy, e.g. corticosteroids, are necessary.Warning 2Hypersensitivity to artesunate including cases of anaphylaxis have been reported during the use of parenteral artesunate (including Artesunate for Injection) . If hypotension, dyspnea, urticaria, or generalized rash occurs during administration of Artesunate for Injection, consider discontinuing Artesunate for Injection administration and continuing therapy with another antimalarial drug.Warning 3Artesunate should not be used during the first trimester of pregnancy.Gen-M Iv/Im Additional InformationPregnancy categoryAlways consult your physician before using any medicine.Storage (YES/NO)Store this medicine at room temperature, away from direct light and heat.

Gen-M Tablets SpecificationRequires Prescription (YES/NO)YesGenericsArtemether , Lumefantrine Used ForMalariaHow it worksBoth components Artemether/ Lumefantrine have their own action site in the malarial parasite. The presence of the endoperoxide bridge in Artemether (generating single oxygen and free radicals, those are very cytotoxic to the plasmodia) appears to be essential for antimalarial activity.Gen-M Tablets Usage And SafetyDosageArtemether , Lumefantrine Side EffectsVery Common: Palpitations, headache, dizziness, abdominal pain, anorexia, vomiting, nausea, arthralgia, mylagia, asthenia, fatigue, sleep disorders.Common: Amnesia, paraesthesia, diarrhea, pruritus, rash, cough, electrocardiogram QT prolongation, gait disturbances, insomia.Uncommon: Liver function test increased, clonus, hypoesthesia, ataxia, somnolence.Drug InteractionsCYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, cimetidine, HIV protease inhibitors, etc.) , CYP2D6 inhibitors (e.g. flecainide, metoprolol, imipramine, amitryptyline, clomipramine, etc.) , Mefloquine.IndicationUsed in the treatment of Malaria.When not to UseIt is contraindicated to those patients which have a history of hypersensitivity to Artemether / Lumefantrine.Gen-M Tablets PrecautionsPrecautionDue to limited data on safety and efficacy, Artemether+Lumefantrine should not be given concurrently with any other anti-malarial agent unless there is no other treatment option.Gen-M Tablets WarningsWarning 1Caution is advised when administering Artemether + Lumefantrine to patients with severe renal, hepatic or cardiac problems. In such cases, monitoring of the ECG is recommended and steps should be taken to correct any electrolyte disturbances.Warning 2Caution is recommended when combining Artemether + Lumefantrine with drugs exhibiting variable patterns of inhibition, induction or competition for CYP3A4 as the therapeutic effects of some drugs could be altered.Warning 3Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be greater.Gen-M Tablets Additional InformationPregnancy categoryAlways consult your physician before using any medicine.Storage (YES/NO)Store this medicine at room temperature, away from direct light and heat.